Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

BACKGROUND: Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET). METHODS: This is a pooled analysis of two multicentre, randomised non-comparative phase 2 clinical trials evaluating neoadjuvant anastrozole an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, Quenel-Tueux, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078275/
https://www.ncbi.nlm.nih.gov/pubmed/32001832
http://dx.doi.org/10.1038/s41416-020-0733-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078275/
https://www.ncbi.nlm.nih.gov/pubmed/32001832
http://dx.doi.org/10.1038/s41416-020-0733-x

Ejemplares similares